MHRA Publishes Ongoing Public List of Suspended and Revoked Medicines Licences
The MHRA maintains a public register of suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredients in the UK. The document functions as a live regulatory record rather than a one-time announcement, and its repeated updates show how closely medicines supply oversight depends on active enforcement. The page was first published on 18 December 2014 and was last updated on 15 October 2026.
The register matters because manufacturing and wholesale authorisations sit at the center of medicine quality and traceability. When a licence is suspended or revoked, the regulatory concern is not abstract paperwork; it speaks directly to whether a company can lawfully make, store, or distribute medicinal products and ingredients. In practice, the list gives pharmacists, procurement teams, healthcare providers, and supply-chain partners a current reference point for companies that have lost the legal authority to operate in those capacities.
The page is structured as a public list of companies in the UK whose licence or registration to manufacture or wholesale medicines or ingredients has been revoked or suspended. No product-specific claims appear in the update log itself, and no company-level details are provided in the scraped text beyond the existence of the ongoing list. What stands out is the cadence of revision: the record has been updated repeatedly over years, with dozens of entries across 2019 through 2026.
One sentence captures the regulatory weight of the page: a suspension changes the legal status of a medicines business immediately.
Repeated Updates Point to Continuous Oversight
The update history shows near-continuous maintenance of the suspended and revoked lists. Entries appear throughout 2020, 2021, 2022, 2023, 2024, 2025, and 2026, with individual updates tied to refreshed attachments, revised CSV files, and replacement lists for suspended or revoked authorisations. Some entries refer to suspended lists alone, while others reflect combined updates to both suspended and revoked records.
That pattern is important for operational reasons. Medicines distribution networks do not stop and start on a convenient schedule; they move through hospitals, community pharmacies, wholesalers, and ingredient suppliers every day. A stale registry would create real risk, especially if a firm that has lost authorisation remained visible as active in downstream procurement systems. By keeping the list current, the MHRA reduces the chance that a non-compliant manufacturer or wholesaler stays embedded in ordinary purchasing or dispensing workflows.
The page also reflects a clear distinction between suspension and revocation. Suspension implies a temporary loss of authorization, while revocation removes the authorization altogether. In either case, the regulator is signaling that the company no longer has the freedom to operate within the relevant medicines framework. For clinicians and medicines management teams, the practical consequence is the same: the company should not be treated as an approved source until its status changes again on the official register.
Medicines Supply Chain Safety Depends on Regulatory Visibility
Public listing is a safeguard in itself. Medicines quality failures can arise far upstream of the bedside, long before a patient sees a prescription label or a vial reaches a ward. Manufacturing controls, wholesale handling practices, and ingredient oversight all shape whether a product remains safe, authentic, and traceable. When a licence is suspended or revoked, the public register becomes a frontline tool for protecting the chain of custody that underpins therapeutic reliability.
This also serves a second function: it preserves trust in the wider market. Wholesale medicines activity depends on confidence that each link in the chain is operating under valid authorization. A public revocation list does not merely punish a single company; it reassures buyers that the regulator is monitoring compliance and making those decisions visible. In sectors where counterfeit risk, storage failures, documentation lapses, or quality-system breakdowns can have downstream clinical consequences, transparency is not administrative ornamentation. It is part of the safety architecture.
The document’s long revision trail suggests that this is a standing regulatory utility, not a temporary file. The list is updated as new suspensions are added, revoked authorisations are replaced, and older entries are refreshed or removed. One 2020 update even notes that suspended licences were adjusted to show entries that had been terminated or revoked and were therefore no longer suspended. That kind of housekeeping matters because the difference between a current suspension and a terminated revocation is legally consequential, even if both imply that the company cannot be treated as an active authorized supplier.
What the Public Record Does and Does Not Tell Readers
The scraped page offers a narrow but important public function: it identifies which companies have lost medicines manufacturing or wholesaling permission and keeps that information current. It does not explain the reasons behind each individual enforcement action in the text provided, and it does not attach clinical outcomes to any specific listing. The value of the page lies in its transparency and timeliness.
For patients, the relevance is indirect but real. A stable medicines supply chain supports access, continuity, and confidence in product quality. For prescribers and pharmacists, the list is a practical check against unapproved supply sources. For procurement leads and wholesalers, it is a compliance document that can inform vendor screening and contracting decisions. In a tightly regulated market, visibility into who has been suspended or revoked is part of preventing unsafe or unauthorized medicines from circulating.
The update history shows that this is not a static archive. It is an active regulatory ledger, refreshed whenever the status of manufacturers or wholesalers changes. That ongoing maintenance is the point: medicines oversight does not end with the grant of a licence, and public accountability does not end with the first enforcement action. The register keeps the market aligned with the current legal status of the firms that move medicines and ingredients through the UK supply chain.